Table 1.

Clinical demographics of LN and GD cohort.

Age in years (range)		LN Patients Average = 35.9 (20.5–67)		UPCR
		GD Patients Average = 48.4 (19–73)		LN Patient	Lupus Class	Active UPCR (mg/g)	GD Patient	UPCR (mg/g)
Sex (%)	LN patients			1	III/V	1151	1	4940
		Female	33/38 (86.8)	2	III	2073	2	4901
		Male	5/38 (13.2)	3	IV	1173	3	9538
				4	IV	2250	4	7708
	GD Patients			5	III/V	783	5	4357
		Female	4/11 (36.4)	6	III/V	1307	6	7303
		Male	7/11 (63.6)	7	IV	1329	7	11,000
Race (%)	LN Patients			8	IV	1509	8	10,000
		African American	29/38 (76.3)	9	IV	1333	9	1171
		White	8/38 (21.1)	10	IV/V	2645	10	4483
		Asian	1/38 (2.6)	11	III/V	1859	11	4571
	GD Patients			12	IV/V	3507
		African American	1/11 (9.1)	13	IV/V	1489
		White	7/11 (63.6)	14	V	1439
		Asian	2/11 (18.2)	15	III/V	905
		Other	1/11 (9.1)	16	IV	1554
				17	IV/V	2928
Anti DS DNA Positive			27/37 (73.0)	18	IV/V	1712
Low C3/C4 (%)			23/37 (62.3)	19	IV/V	4791
Lupus Class (%)				20	IV	3633
		III	3/38 (7.9)	21	IV/V	2354
		IV	10/38 (26.3)	22	III	2679
		V	6/38 (15.8)	23	III	923
		III/V	8/3 (21.1)	24	V	1769
		IV/V	11/38 (28.9)	25	IV	2746
				26	V	12,681
Immunosuppression at collection of samples (%)				27	V	1066
Mycophenolate			33/38 (86.8)	28	IV/V	1768
Prednisone			27/38 (71.1)	29	IV	1127
Hydroxycholorquine			26/38 (68.4)	30	III/V	3553
Belimumab			5/38 (13.2)	31	III/V	1355
Methotrexate			1/38 (2.6)	32	III/V	1513
Tacrolimus			4/38 (10.5)	33	IV	2427
Cyclophosphamide			4/38 (10.5)	34	IV/V	6355
Rituximab			4/38 (10.5)	35	IV/V	14,611
				36	IV/V	928
				37	V	3819
				38	V	1229